Browsing by Author "Griffin, Julian L."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Adaptive changes of the Insig1/SREBP1/SCD1 set point help adipose tissue to cope with increased storage demands of obesity
    (American Diabetes Association, 2013-11) Carobbio, Stefania; Hagen, Rachel M.; Lelliott, Christopher J.; Slawik, Marc; Medina-Gomez, Gema; Tan, Chong-Yew; Sicard, Audrey; Atherton, Helen J.; Barbarroja, Nuria; Bjursell, Mikael; Bohlooly-Y, Mohammad; Virtue, Sam; Tuthill, Antoinette; Lefai, Etienne; Laville, Martine; Wu, Tingting; Considine, Robert V.; Vidal, Hubert; Langin, Dominique; Oresic, Matej; Tinahones, Francisco J.; Manuel Fernandez-Real, Jose; Griffin, Julian L.; Sethi, Jaswinder K.; López, Miguel; Vidal-Puig, Antonio; Medicine, School of Medicine
    The epidemic of obesity imposes unprecedented challenges on human adipose tissue (WAT) storage capacity that may benefit from adaptive mechanisms to maintain adipocyte functionality. Here, we demonstrate that changes in the regulatory feedback set point control of Insig1/SREBP1 represent an adaptive response that preserves WAT lipid homeostasis in obese and insulin-resistant states. In our experiments, we show that Insig1 mRNA expression decreases in WAT from mice with obesity-associated insulin resistance and from morbidly obese humans and in in vitro models of adipocyte insulin resistance. Insig1 downregulation is part of an adaptive response that promotes the maintenance of SREBP1 maturation and facilitates lipogenesis and availability of appropriate levels of fatty acid unsaturation, partially compensating the antilipogenic effect associated with insulin resistance. We describe for the first time the existence of this adaptive mechanism in WAT, which involves Insig1/SREBP1 and preserves the degree of lipid unsaturation under conditions of obesity-induced insulin resistance. These adaptive mechanisms contribute to maintain lipid desaturation through preferential SCD1 regulation and facilitate fat storage in WAT, despite on-going metabolic stress.
  • Thumbnail Image
    Item
    Hematopoietic IKBKE limits the chronicity of inflammasome priming and metaflammation
    (PNAS, 2015-01-13) Patel, Meghana N.; Bernard, William G.; Milev, Nikolay B.; Cawthorn, William P.; Figg, Nichola; Hart, Dan; Prieur, Xavier; Virtue, Sam; Hegyi, Krisztina; Bonnafous, Stephanie; Bailly-Maitre, Beatrice; Chu, Yajing; Griffin, Julian L.; Mallat, Ziad; Considine, Robert V.; Tran, Albert; Gual, Philippe; Takeuchi, Osamu; Akira, Shizuo; Vidal-Puig, Antonio; Bennett, Martin R.; Sethi, Jaswinder K.; Department of Medicine, IU School of Medicine
    Obesity increases the risk of developing life-threatening metabolic diseases including cardiovascular disease, fatty liver disease, diabetes, and cancer. Efforts to curb the global obesity epidemic and its impact have proven unsuccessful in part by a limited understanding of these chronic progressive diseases. It is clear that low-grade chronic inflammation, or metaflammation, underlies the pathogenesis of obesity-associated type 2 diabetes and atherosclerosis. However, the mechanisms that maintain chronicity and prevent inflammatory resolution are poorly understood. Here, we show that inhibitor of κB kinase epsilon (IKBKE) is a novel regulator that limits chronic inflammation during metabolic disease and atherosclerosis. The pathogenic relevance of IKBKE was indicated by the colocalization with macrophages in human and murine tissues and in atherosclerotic plaques. Genetic ablation of IKBKE resulted in enhanced and prolonged priming of the NLRP3 inflammasome in cultured macrophages, in hypertrophic adipose tissue, and in livers of hypercholesterolemic mice. This altered profile associated with enhanced acute phase response, deregulated cholesterol metabolism, and steatoheptatitis. Restoring IKBKE only in hematopoietic cells was sufficient to reverse elevated inflammasome priming and these metabolic features. In advanced atherosclerotic plaques, loss of IKBKE and hematopoietic cell restoration altered plaque composition. These studies reveal a new role for hematopoietic IKBKE: to limit inflammasome priming and metaflammation.